Identification of Biomarkers in the Legal Medical Skin Wounds
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02898636|
Recruitment Status : Unknown
Verified September 2015 by University Hospital, Montpellier.
Recruitment status was: Recruiting
First Posted : September 13, 2016
Last Update Posted : September 13, 2016
|Condition or disease||Intervention/treatment|
|Legal Medical Skin Wounds||Other: autopsy|
Determining the vitality of skin wounds, that is to say their antemortem character, is an important issue in forensic pathology. The only criterion vitality currently recognized (but whose diagnostic performance remains limited) is the microscopic demonstration of an inflammatory infiltrate of neutrophils. The search for more reliable diagnostic biomarkers is required. By their early expression of the injury site, inflammatory cytokines are potential candidates and their quantification in injured skin could optimize the diagnosis of vitality injury.
The objective is to identify the cytokine or combination of cytokines, with the best diagnostic performance to characterize the vital nature of a skin wound in the body.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Identification of Protein Markers of Vitality in Skin Wounds by Forensic Multiplex Analysis|
|Study Start Date :||September 2016|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||March 2018|
- Other: autopsy
At autopsy achieving adequate sampling of lesions and healthy skin
- measures cytokines [ Time Frame: 1 day ]multiplex analysis electrochemoluminescence: Six cytokines candidates selected from a literature review (IFN-γ, IL-1β, IL-6, IL-10, IL-12 p70, TNF-α) will be assayed in conjunction with the MSD technology (V-PLEX proinflammatory Panel 1 human Kit) after tissue extraction and determination of total protein concentration in each sample.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02898636
|Contact: Pierre-Antoine PEYRON, MD||467338586 ext firstname.lastname@example.org|
|Montpellier, France, 34295|
|Study Director:||Pierre-Antoine PEYRON, MD||University Hospital, Montpellier|